Axogen rises after FDA approves co's nerve repair graft

AxoGen

04/12/2025 11:12

** Shares of Axogen AXGN.O gain 9.3% at $30.99 premarket after FDA approves its nerve repair graft

** Avance Nerve Graft, a human tissue-based product, is designed to repair damaged peripheral nerves without requiring second surgery to harvest nerve tissue from the patient

** Approval of the nerve graft paves the way for up to 12 years of potential U.S. market exclusivity, analysts say

** Commercial sales of the licensed Avance product expected to begin early Q2 2026; until then, product continues under existing tissue framework

** FDA approval reclassifies Avance as a biologic for treatment of sensory nerve discontinuities in adults and pediatric patients aged one month and older

** AXGN stock up 71.9% YTD, as of last close

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))